news
Using immunotherapy to prevent cancer metastases
Scientists have demonstrated how killer T cells used in immunotherapy to eliminate cancer cells can also destroy tumour lymphatic vessels, thus greatly reducing the risk of metastasis.
List view / Grid view
T cells
news
New study uncovers the dynamics of adaptive immunity in tuberculosis
A new study has provided insights into how a novel tuberculosis vaccine strategy could work by speeding up the T cell responses in the lungs to shut down infection rapidly.
news
Biodegradable gel boosts immune system’s attack on several cancers in mice
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
whitepaper
Product hub: Drive your drug discovery with an enhanced live cell metabolic assay platform
13 April 2022 | By
Detect rapid, real-time changes in cellular bioenergetics with a platform optimised for pharma.
article
Viewing disease through the lens of memory B cells: improving cancer and infectious disease treatment
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
article
How to develop the next generation of CAR T-cell therapies
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
article
Triggering ferroptosis in cancer cells
A new study from the University of Michigan Rogel Cancer Center, US has revealed that a cytokine and a fatty acid can work together to trigger ferroptosis. Here, Dr Weiping Zou, the lead researcher from the study, outlines how this process could be used to target cancer cells and enhance immunotherapies.
whitepaper
Bulletin: Utilising the multiparameter capability of the Ze5 Cell Analyser to monitor T cell exhaustion and effects of immunotherapy
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
news
Study highlights the essential role of dendritic cells in immunotherapy
Researchers have discovered how immune system dendritic cells are key to maintaining and regulating response to immunotherapy.
news
New CRISPR gene-editing technology could lead to better treatments for HIV
Scientists at Northwestern Medicine have developed new techniques in human blood to pave potential paths towards a HIV cure.
article
Drug Target Review Immuno-oncology ebook 2022
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
news
Novel genome-wide approach to engineer more effective immunotherapy
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
news
Research reveals CDH17 represents a new approach to treat solid cancers
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
news
CAR T-cell implant effective at attacking cancer in pre-clinical study
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
news
Discovery could advance CAR T-cell therapy
Scientists have found a way to “supercharge” tumour-attacking T cells, which could improve the effectiveness of cell-based cancer immunotherapy and expand the number of cancers it can treat.